Immortalized Cell Line Market Research Report Information by Method (Virus Induction, HTERT Expression, Inactivation of Tumor Suppression Genes and others), Application (Diagnostics, Drug Discovery, Vaccine Production, Tissue Engineering and Regenerative Medicines and others), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations and Research Laboratories) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2032

Global Immortalized Cell Line Market Overview

The Immortalized Cell Line Market Size was valued at USD 4.23 Billion in 2023. The Global Immortalized Cell Line industry is projected to grow from USD 4.51 Billion in 2024 to USD 7.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.67% during the forecast period (2024 - 2032). Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. These cell lines are expected to grow due to the rise in vaccine production and innovative technologies. Besides, the ability of cell line culture to provide more physiologically relevant information and more accurate data in-vitro tests has led cell line culture systems to become acceptable in comparison to media culture.

 

The increasing application in biotech and pharmaceutical companies and hospitals, a growing number of patients in need of organ transplantation, and the rise in the patient population affected by cancer are the major drivers propelling market growth. However, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination may hinder the growth of the market.

February 2024

For the first time ever, the revolutionary spontaneously immortalized bovine myoblast cell line known as PROFUSE-B8 has been formally introduced, and it is now available for licensing. In announcing its official debut, ProFuse Technology is glad to share the news. This recent achievement, which marks a significant milestone in the field of farmed meat, has resulted in the introduction of a paradigm shift in the efficient growth of muscle tissue that is rich in protein.

The PROFUSE-B8 cell line, which has been the subject of significant study and testing over the course of a full two-year period, provides cultured meat manufacturers with a solid and robust foundation for the establishment of scalable, repeatable, and cost-competitive production processes. This has been accomplished by testing and researching the cell line over the course of two years. It is important to note that B8 is able to do this without using any method that includes genetic alteration. This ensures that it is in complete accordance with the preferences and consent of customers.

Its revolutionary features are complimented by the fact that, when taken with the PROFUSE-S1 muscle differentiation media supplement, the synthesis of muscle tissue is speed up, which results in increased productivity in a shorter length of time. This is a significant advantage.

ProFuse Technology is 100% committed to advancing the cultured meat business by providing cutting-edge solutions for the production of muscle-related goods. This commitment is steadfast. At the same time, the company is making significant progress toward the development of other muscle production-optimized cell lines that are tailored to the unique requirements of chicken, hog, lamb, and fish for specialized purposes.

According to Dr. Tamar Eigler-Hirsh, Chief Technology Officer and Co-Founder of ProFuse Technology, in a statement, "We are thrilled to introduce PROFUSE-B8 as a transformative solution for the cultivated meat industry." "Our dedication to innovation and productivity is evident in the development of this breakthrough cell line, and we are confident it will shape the future of cell based protein production."

Immortalized Cell Line Market Trends

The increasing demand for organ donation due to scarcity in the availability of organs is driving the need for artificially created biological cells. For instance, according to the US Department of Health & Human Services Organ Procurement and Transplantation Network (OPTN), as of November 2016, 121,678 patients were waiting for a life-saving organ transplant. This rising demand for an

organ transplant

is expected to drive the growth of the market during the forecast period. Additionally, increasing application in biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer are likely to support market growth. On the other hand, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination is anticipated to hamper the market growth.

Immortalized Cell Line Market Segment Insights

The immortalized cell line market has been segmented into method, application, and end user. 

Immortalized Cell Line Method Insights

Based on the method, the global market has been segmented into virus induction, hTERT expression, inactivation of tumor suppression genes, and others. The virus induction segment is further divided into EBV genes, SV40 T antigen, HPV-16 E6/6 gene, and others. The hTERT expression segment is sub-segmented into P53 and Myc T58A.

Immortalized Cell Line Application Insights

The immortalized cell line market, based on application, is segmented into diagnostics, drug discovery, vaccine production, 

tissue engineering

and regenerative medicine, and others.

Immortalized Cell Line End User Insights

Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017.  

Some of the key strategies followed by the players operating in the immortalized cell line market are innovation, product development, acquisition, and expansion.

Immortalized Clinell Line Market Regional Insights

The immortalized cell e market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is estimated to dominate the immortalized cell line market during the forecast period. This is attributed to an increase in the occurrence of cancer, the presence of well-established pharmaceutical and biotechnology industry, increasing awareness of immortalized cell lines, and strong research funding.

The European market for immortalized cell line is expected to be the second-largest during the forecast period. Increasing government support, well-developed technology, and rising cases of cancer are expected to boost the growth of the market in this region.    

Asia-Pacific is estimated to be the fastest-growing market due to the increasing expenditure on healthcare by government and private sector companies. Moreover, the growing awareness about healthcare and large untapped patient population have led to the increased focus of key players on expansion in this region. Furthermore, the region accounted for a market share of 17.8% in 2017.

The immortalized cell line market in the Middle East & Africa is expected to hold the least market share.

Immortalized Cell Line Market Key Players

The prominent players in the immortalized cell line market are 

• Thermo Fisher Scientific (US)


• ATCC (American Type Culture Collection Inc.) (US)


• Valneva (France), 


• 
  Sartorius AG (Germany)


• Lonza Group, AG (Switzerland)


• Merck KGaA (Germany)


• Selexis SA (Switzerland)


• WuXi App Tec (China)


• European Collection of Authenticated Cell Cultures (ECACC) (Europe)


• Corning Incorporated (US)

Immortalized Cell Line Industry Developments
In January 2024,

Thermo Fisher Scientific Launched new Gibco™ Advanced DMEM/F12 media optimized for immortalized cell lines, claiming improved growth and performance.

In September2023,

Lonza Group AG Announced partnership with CStone Pharmaceuticals to optimize and manufacture immortalized cell lines for CAR-T cell therapy development.

Immortalized Cell Line Market Segmentation

Immortalized Cell Line Method Outlook

• Virus Induction


• EBV genes


• SV40 T antigen


• HPV-16 E6/6 gene


• Others 


• HTERT Expression


• P53


• Myc T58A


• Inactivation of Tumour Suppression Genes


• Others

Immortalized Cell Line Application Outlook

• Diagnostics


• Drug Discovery


• Vaccine Production


• Tissue Engineering and Regenerative Medicines


• Others

Immortalized Cell Line End User Outlook

• Pharmaceutical and Biopharmaceutical Companies


• Contract Research Organizations


• Research Laboratories

Immortalized Cell Line Regional Outlook

• Americas




• North America




• US


• Canada




• 
  South America
  

• Europe




• Western Europe




• Germany


• UK


• France


• Italy


• Spain


• Rest of Western Europe




• 
  Eastern Europe
  

• Asia-Pacific




• China


• Japan


• India


• South Korea


• Rest of Asia-Pacific

• Middle East & Africa




• Middle East


• Africa

Intended Audience

• Research and development (R&D) companies


• Government research institutes


• Academic institutes and universities

Attribute/Metric	Details
Market Size 2032	USD 7.56 Billion
CAGR	6.67% (2024-2032)
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Method, Application, End User and Region
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Virus Induction, EBV genes, SV40 T antigen, HPV-16 E6/6 gene, HTERT Expression, Myc T58A, Inactivation of Tumour Suppression Genes
Key Market Opportunities	Increasing demand for organ donation due to scarcity in the availability of organs
Key Market Drivers	Increasing government support, well-developed technology